Target-specific immunoPET Imaging of Breast Cancer
Recruiting · NCT06715826 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
[18F]F-RESCA-RB14[18F]F-RESCA-RT4
What this trial is about
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Who can take part
Age range
18 Years to 75 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Aged 18-75 years old and of female gender；
- Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;
- Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
Exclusion criteria
- Pregnancy；
- Severe hepatic and renal insufficiency;
- History of serious surgery in the last month;
- Allergic to antibody or single-domain antibody radiopharmaceuticals.
Where it is running
1 location listed.
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University - Shanghai, Shanghai Municipality, China